sec.Hexyl-p-tolylether

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: sec.Hexyl-p-tolylether
• 英文别名: 1-Hexan-2-yloxy-4-methylbenzene
• 化学式: C₁₃H₂₀O
• 分子量: 192.301
• InChiKey: WGWIZDONPRVIJZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  对甲酚 、 正己醇 在 三氟化硼 作用下， 以 四氯化碳 为溶剂， 生成 sec.Hexyl-p-tolylether
  参考文献：
  名称：

  Romadan,I.A.; Weinberg,M.M., Journal of General Chemistry of the USSR, 1964, vol. 34, p. 1547 - 1551

  摘要：

  DOI：

文献信息

• [EN] NOVEL 5-AMINO-2-THIOIMIDAZOLE COMPOUNDS AND THEIR USE<br/>[FR] NOUVEAUX COMPOSÉS 5-AMINO-2-THIO-IMIDAZOLES ET LEUR UTILISATION
  申请人：UNIV LILLE II DROIT & SANTE

  公开号：WO2017042380A1

  公开（公告）日：2017-03-16

  The present invention is directed to novel compounds of formula (I) pharmaceutically acceptable salts or solvates thereof, and their use.

  本发明涉及公式(I)的新化合物，其药用盐或溶剂，以及它们的用途。
• Catalytic S _N Ar Hydroxylation and Alkoxylation of Aryl Fluorides
  作者：Qi‐Kai Kang、Yunzhi Lin、Yuntong Li、Lun Xu、Ke Li、Hang Shi

  DOI：10.1002/anie.202106440

  日期：2021.9.6

  mechanism of SNAr reactions involving metal arene complexes is hypothesized to involve a stepwise pathway (addition followed by elimination), experimental data that support this hypothesis is still under exploration. Mechanistic studies and DFT calculations suggest either a stepwise or stepwise-like energy profile. Notably, we isolated a rhodium η5-cyclohexadienyl complex intermediate with an sp3-hybridized

  亲核芳香取代 (S N Ar) 是一种通过用亲核试剂取代离去基团将杂原子结合到芳香环中的强大策略，但这种方法仅限于缺电子芳烃。我们现在已经建立了一种通过催化 S N Ar 反应获取苯酚和苯基烷基醚的可靠方法。该方法适用于广泛的富电子和中性芳基氟化物，它们在经典的 S N Ar 条件下呈惰性。虽然 S N的机制假设涉及金属芳烃配合物的 Ar 反应涉及逐步途径（添加后消除），支持该假设的实验数据仍在探索中。机械研究和 DFT 计算表明了一个逐步或逐步的能量分布。值得注意的是，我们分离了铑 η 5 -环己二烯基复合中间体，其具有带有亲核试剂和离去基团的 sp 3 -杂化碳。
• Norvaline Derivative and Method for Preparation Thereof
  申请人：Harada Naoyuki

  公开号：US20080076769A1

  公开（公告）日：2008-03-27

  Norvaline derivative of the formula [I] or pharmaceutically acceptable salt thereof, method for preparing the same, pharmaceutical composition containing the same, and use of said compound for inhibiting transporting activity of glycine transporter type 2 (GlyT2). [wherein X is —CH 2 —, —O—, —S— or single bond; Ar is optionally substituted aryl or lower cycloalkyl; n is 0 to 2; R 1 and R 2 are (i) each is hydrogen or lower alkyl; (ii) R 1 and R 2 are combined to form lower alkylene; or (iii) R 1 is hydrogen or lower alkyl and R 2 is combined with R 4 or R 6 to form lower alkylene; R 3 and R 4 are (i) each is hydrogen or lower alkyl; (ii) R 3 and R 4 are combined to form lower alkylene; or (iii) R 3 is hydrogen or lower alkyl and R 4 is combined with R 2 or R 6 to form lower alkylene; R is or —OR 7 ; R 5 and R 6 are (i) each is optionally substituted lower alkyl, or hydrogen; (ii) R 5 and R 6 are combined to form aliphatic 5- to 6-membered heterocyclic group; or (iii) R 5 is optionally substituted lower alkyl or hydrogen and R 6 is combined with R 2 or R 4 to form lower alkylene; R 7 is lower alkyl.

  Norvaline衍生物的化学式[I]或其药学上可接受的盐，制备方法，含有该化合物的药物组合物，以及用于抑制甘氨酸转运体2型（GlyT2）的转运活性的用途。[其中X为-CH2-，-O-，-S-或单键；Ar为可选取代芳基或较低的环烷基；n为0至2；R1和R2为（i）氢或较低的烷基；（ii）R1和R2结合形成较低的烷基；或（iii）R1为氢或较低的烷基，R2与R4或R6结合形成较低的烷基；R3和R4为（i）氢或较低的烷基；（ii）R3和R4结合形成较低的烷基；或（iii）R3为氢或较低的烷基，R4与R2或R6结合形成较低的烷基；R为-OH或-OR7；R5和R6为（i）可选取代的较低烷基或氢；（ii）R5和R6结合形成脂肪族5-至6-成员杂环基；或（iii）R5为可选取代的较低烷基或氢，R6与R2或R4结合形成较低的烷基；R7为较低烷基。
• Silver Beta-Ketocarboxylate, Material Comprising the Same for Forming Silver Metal, and Use Thereof
  申请人：Suganuma Katsuaki

  公开号：US20090209693A1

  公开（公告）日：2009-08-20

  It is an object to provide a novel material that can quickly form metal silver even at a low temperature of approximately 210° C. or less. This serves as a metal silver forming material that includes a silver β-ketocarboxylate. By heating this forming material, it is possible to form metal silver quickly even at a low temperature of approximately 210° C. or less. Examples of the silver β-ketocarboxylate include silver isobutyrylacetate, silver benzoylacetate, silver acetoacetate, silver propionylacetate, silver α-methylacetoacetate, and silver α-ethylacetoacetate.

  本发明旨在提供一种新型材料，能够在低至约210°C的温度下快速形成金属银。这种金属银形成材料包括银β-酮酸盐。通过加热这种形成材料，即使在低至约210°C的温度下，也可以快速形成金属银。银β-酮酸盐的例子包括异丁酰乙酸银、苯甲酰乙酸银、乙酰乙酸银、丙酰乙酸银、α-甲基乙酰乙酸银和α-乙基乙酰乙酸银。
• NORVALINE DERIVATIVE AND METHOD FOR PREPARATION THEREOF
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP1846366B1

  公开（公告）日：2011-08-03